| Mrs Lauren Jane Burke, MS OTR/L | |
|
12080 Bellaire Way, Thornton, CO 80241-3600 | |
| (303) 450-2700 | |
| Not Available |
| Full Name | Mrs Lauren Jane Burke |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 12080 Bellaire Way, Thornton, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215486303 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OT.0004762 (Colorado) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Lauren Jane Burke, MS OTR/L 1620 Fillmore St, Apt. 421, Denver, CO 80206-1616 Ph: (406) 980-0523 | Mrs Lauren Jane Burke, MS OTR/L 12080 Bellaire Way, Thornton, CO 80241-3600 Ph: (303) 450-2700 |
News Archive
The Canadian Society of Diagnostic Medical Sonographers (CSDMS) and the Canadian Association of Registered Diagnostic Ultrasound Professionals (CARDUP) are making a presentation to the Ontario Legislative Assembly Standing Committee on Social Policy studying Bill 179 (the Regulated Health Professions Statute Law Amendment Act, 2009).
Lung cancer is the leading cause of cancer death among men and women. About 85 percent of lung cancers are non-small cell lung cancer. For a handful of these patients, therapies that target specific genetic mutations are effective.
LifePoint Hospitals, Inc. today announced that its Board of Directors, at a regularly scheduled meeting, has authorized a new stock repurchase program that will allow for repurchases of up to $250 million of its common stock over the next 18 months. Amounts available under the Company's previously announced share repurchase program were exhausted during the current fiscal quarter.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
The American Academy of Neurology is pleased to announce the winning entries to the 2016 Neuro Film Festival.
› Verified 5 days ago
Optimistic Therapy Resource Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2207 E 102nd Ave, Thornton, CO 80229 Phone: 720-204-0423 | |
Dr. Theresa Gonzalez, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 E 128th Ave, Thornton, CO 80241 Phone: 303-453-0135 | |
Sharon Disney, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15768 Valentia St, Thornton, CO 80602 Phone: 303-801-8282 | |
Ms. Kayla Dawn Cook, MSOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9726 Dexter Lane, Thornton, CO 80229 Phone: 720-231-0473 | |
Danielle Mitchell, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 12080 Bellaire Way, Thornton, CO 80241 Phone: 303-450-2700 | |
Mrs. Rachel Dawn Craig, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1500 E 128th Ave, Thornton, CO 80241 Phone: 720-425-3965 | |
Mrs. Julie A Yancey, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9195 Grant St, Suite 100, Thornton, CO 80229 Phone: 303-451-7700 Fax: 303-252-9474 |